SCHEMBL4860832

SCHEMBL4860832

O=c1c([N+](=O)[O-])c(-c2cnn(Cc3ccccc3F)c2)n(C2CCC2)c(=O)n1Cc1ccncc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 2/20 0.38
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38
NPSR1 Q6W5P4 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 1/20 0.35
CRHBP P24387 1/20 0.35
CRHR2 Q13324 1/20 0.35
MAPT P10636 2/20 0.35
ALDH1A1 P00352 3/20 0.35
PKM P14618 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
CYP3A4 P08684 5/20 0.34
CYP2D6 P10635 4/20 0.34
PDE4A P27815 1/20 0.33
MAP3K5 Q99683 1/20 0.32
ALK Q9UM73 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4895305 0.90 ADORA2A (0.40) ADORA2BADORA2AADORA1
SCHEMBL4868092 0.88 ADORA2B (0.40) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2
SCHEMBL4866634 0.87 ADORA2B (0.45) ADORA2BADORA2AADORA1SMN1; SMN2MAPT
SCHEMBL4763921 0.86 NPSR1 (0.33) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2
SCHEMBL4763924 0.86 NPSR1 (0.33) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2
SCHEMBL4867818 0.83 ADORA2B (0.39) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2
SCHEMBL4867852 0.83 PARG (0.37) CYP3A4CYP2D6PDE4A
SCHEMBL4866193 0.83 PDE4A (0.39) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2
SCHEMBL4859881 0.81 ADORA2B (0.40) ADORA2BADORA2AADORA1SMN1; SMN2MAPT
SCHEMBL4766214 0.80 ADORA2B (0.46) ADORA2BADORA2AADORA1NPSR1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7449473-B2 Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonists CV THERAPEUTICS, INC. (US) 2008-11-11 US disclosed
EP-1678181-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2006-07-12 EP disclosed
US-20050119287-A1 A2B adenosine receptor antagonists GILEAD PALO ALTO, INC. 2005-06-02 US disclosed
WO-2005042534-A2 A2B ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. (US) 2005-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119287-A1 A2B adenosine receptor antagonists ADORA2B, ADORA2A, ADORA3 ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.